Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 2c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q2 EPS of ($0.40), $0.02 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $14.42 million versus the consensus estimate of $11.96 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Goldman: 'Our key conclusion is that AI is likely to be credit-positive for banks', 'Rearming Our Overweight Stance on Banks'
• Lockheed Martin to supply Denmark with helicopters for $425m
• Boeing wins Japan aircraft support deal worth $159 million